With the educational support of:
From 25 January till 27 January 2024: HIGHLIGHTS FROM ASCO GU
Your direct line with San Francisco
The 2024 ASCO Genitourinary Cancers Symposium provides expert, multidisciplinary perspectives on the latest clinical and scientific advances in the field.
Your Belgian colleagues are on site, or follow the program online, and keep you posted about the hottest topics as they happen.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Congress highlights
Professor Emmanuel Seront, medical oncologist at Cliniques Universitaires Saint-Luc in Belgium, provides an overview of key developments in renal cancer presented at ASCO GU 2024.
The initial groundbreaking study, CheckMate-67T, scrutinizes
Prof Christof Vulsteke, medical oncologist at the Integrated Cancer Center, Ghent, provides his selection of highlights on urothelial cancer from ASCO GU 2024.
Professor Bertrand Tombal, affiliated as a urologist at Cliniques Universitaires Saint-Luc in Brussels, provides updates on the proceedings of the ASCO GU 2024.
The GETUG-AFU 18 is a French study
In the spotlight
In this episode, Dr Nieves Martinez-Chanza from the Institut Jules Bordet in Brussels provides a summary of the KN-564 trial, a randomized phase 3 clinical trial assessing the addition of
Dr Marco Gizzi, a medical oncologist at the Grand Hôpital de Charleroi and the Cliniques Universitaires Saint Luc, will present the findings of the AMBASSADOR trial at ASCO GU2024.
Prof Emmanual Seront, medical oncologist at Cliniques Universitaires Saint-Luc, guides us through the update of the CheckMate 9ER trial that was presented at ASCO GU 2024.
This well-known randomized phase
With the educational support of:
